• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Enfusion Inc.

    5/1/25 4:15:29 PM ET
    $ENFN
    Computer Software: Prepackaged Software
    Technology
    Get the next $ENFN alert in real time by email
    15-12G 1 d916980d1512g.htm 15-12G 15-12G
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-40949

     

     

    Enfusion, Inc.*

    (Exact name of registrant as specified in its charter)

     

     

    125 South Clark Street, Suite 750

    Chicago, Illinois 60603

    Telephone number: (312) 253-9800

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Class A Common Stock, par value $0.001 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: None.*

     

    *

    Effective April 21, 2025, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of January 10, 2025, by and among Enfusion, Inc. (“Enfusion”), Clearwater Analytics Holdings, Inc. (“Clearwater”), Poseidon Acquirer, Inc., a wholly-owned subsidiary of Clearwater (“Acquirer”), Poseidon Merger Sub I, Inc., a wholly-owned subsidiary of Clearwater (“Merger Sub”), Poseidon Merger Sub II, LLC, an indirect subsidiary of Clearwater (“Merger Sub II”), and Enfusion Ltd. LLC, a subsidiary of Enfusion (“Enfusion OpCo”), (i) Merger Sub II merged with and into Enfusion OpCo (the “LLC Merger”), with Enfusion OpCo surviving the LLC Merger as an indirect subsidiary of Clearwater, (ii) Merger Sub merged with and into Enfusion (the “First Merger”), with Enfusion surviving the First Merger as a direct, wholly-owned subsidiary of Clearwater (the “Surviving Corporation”), and (iii) the Surviving Corporation merged with and into Acquirer (the “Second Merger”), with Acquirer surviving the Second Merger as a direct, wholly-owned subsidiary of Clearwater.

    Pursuant to the requirements of the Securities Exchange Act of 1934, Enfusion, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Dated: May 1, 2025

       

    Enfusion, Inc.

        By:   /s/ Alphonse Valbrune
       

    Name:

     

    Alphonse Valbrune

       

    Title:

     

    Secretary

     

     
     
    Get the next $ENFN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENFN

    DatePrice TargetRatingAnalyst
    5/10/2024$11.00Overweight
    Morgan Stanley
    2/28/2024$9.00 → $8.00Neutral → Sell
    Goldman
    1/30/2024$11.00 → $9.00Neutral → Underweight
    JP Morgan
    11/7/2023$9.00Neutral
    UBS
    4/3/2023$11.00Neutral
    Piper Sandler
    3/15/2023$12.00Neutral
    JP Morgan
    1/4/2023$15.00 → $10.00Neutral → Underperform
    BofA Securities
    1/3/2023$13.00 → $12.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ENFN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OPENLANE Names Brad Herring Chief Financial Officer

      Bolsters Leadership Bench With More Than 30 Years of Financial Management and Investor Relations Expertise CARMEL, Ind., April 22, 2025 /PRNewswire/ -- OPENLANE, Inc. (NYSE:KAR), a leading operator of digital marketplaces for wholesale used vehicles, announces the company has named Brad Herring as EVP and Chief Financial Officer effective May 27, 2025. Herring will be responsible for leading all financial, reporting and investor-facing functions across OPENLANE, including the company's capital investment strategy. Herring also joins OPENLANE's executive team and will report to CEO Peter Kelly.

      4/22/25 4:15:00 PM ET
      $ENFN
      $FOUR
      $KAR
      Computer Software: Prepackaged Software
      Technology
      Business Services
      Consumer Discretionary
    • Clearwater Analytics Finalizes Acquisition of Enfusion

      Clearwater Will Deliver Industry's First Unified, Cloud-Native Front-to-Back Platform for Institutional Investors Clearwater Analytics (NYSE:CWAN), the most comprehensive technology platform for investment management, today announced the successful completion of its acquisition of Enfusion, Inc. (NYSE:ENFN), a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund sectors, in a deal valued at approximately $1.5 billion. This strategic combination positions Clearwater as the industry's first single-instance, multi-tenant, cloud-native platform to unify front, middle, and back-office investment operations. By integrating portfolio and order management,

      4/21/25 4:15:00 PM ET
      $CWAN
      $ENFN
      Computer Software: Prepackaged Software
      Technology
    • Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration

      Clearwater Analytics (NYSE:CWAN) ("Clearwater") and Enfusion, Inc. (NYSE:ENFN) ("Enfusion") today announced the preliminary results of the elections made by Enfusion shareholders of record regarding the form of merger consideration (the "Merger Consideration") they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction"). As previously disclosed, the deadline to have made such an election was 5:00 p.m. Eastern Time on April 16, 2025 (the "Election Deadline"). The parties expect to close the Transaction on April 21, 2025, subject to the approval of the Transaction by Enfusion shareholders and the satisfaction or waiver of other customary closing conditions

      4/17/25 8:00:00 AM ET
      $CWAN
      $ENFN
      Computer Software: Prepackaged Software
      Technology

    $ENFN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Enfusion with a new price target

      Morgan Stanley resumed coverage of Enfusion with a rating of Overweight and set a new price target of $11.00

      5/10/24 8:40:24 AM ET
      $ENFN
      Computer Software: Prepackaged Software
      Technology
    • Enfusion downgraded by Goldman with a new price target

      Goldman downgraded Enfusion from Neutral to Sell and set a new price target of $8.00 from $9.00 previously

      2/28/24 6:16:11 AM ET
      $ENFN
      Computer Software: Prepackaged Software
      Technology
    • Enfusion downgraded by JP Morgan with a new price target

      JP Morgan downgraded Enfusion from Neutral to Underweight and set a new price target of $9.00 from $11.00 previously

      1/30/24 6:55:00 AM ET
      $ENFN
      Computer Software: Prepackaged Software
      Technology

    $ENFN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Iconiq Strategic Partners V, L.P. disposed of 9,009,594 shares (SEC Form 4)

      4 - Enfusion, Inc. (0001868912) (Issuer)

      4/23/25 4:30:12 PM ET
      $ENFN
      Computer Software: Prepackaged Software
      Technology
    • Director Luo Roy returned 9,009,594 shares to the company (SEC Form 4)

      4 - Enfusion, Inc. (0001868912) (Issuer)

      4/23/25 4:30:09 PM ET
      $ENFN
      Computer Software: Prepackaged Software
      Technology
    • Chief Operating Officer Pawar Neal returned 1,217,308 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Enfusion, Inc. (0001868912) (Issuer)

      4/21/25 5:11:16 PM ET
      $ENFN
      Computer Software: Prepackaged Software
      Technology